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ABSTRACT
Background: While nuts and their related nutrients have been inversely associated with some
cancers, the association between nut consumption and prostate cancer has been inconsistent.
Methods: We conducted an analysis of the association between nut and peanut butter
consumption and risk of incident prostate cancer among 173,243 men in the prospective NIHAARP Diet and Health Study. There was a total of 18,619 incident prostate cancer cases during
the 16 years of follow-up. We calculated hazard ratios (HRs) and 95% confidence intervals (CIs)
using Cox proportional hazards regression for intake of nuts, peanut butter, and total nuts (nuts
plus peanut butter), as well as frequency of nut consumption. We evaluated associations with
overall prostate cancer and the following subtypes: adenocarcinoma, localized, advanced, fatal,
low-grade (Gleason 2-7), and high-grade (Gleason ≥8).
Results: There was no association between nuts (highest versus lowest category HR=1.00, 95%
CI: 0.95, 1.07), peanut butter consumption (HR=1.02, 95% CI: 0.98, 1.07), or total nuts
(HR=1.00, 95% CI: 0.93, 1.09) and prostate cancer. Similarly, there were no associations with
nuts, peanut butter, and total nuts localized, advanced, or fatal prostate cancer in this population.
There was some evidence of an inverse association for frequency of nut consumption and
prostate cancer (highest versus lowest category HR=0.93, 95% CI: 0.88, 0.98), but the p-trend
was not statistically significant (0.07).
Conclusions: In this large prospective cohort study, there was no clear evidence for an
association between nut or peanut butter consumption and prostate cancer. Additional research in
prospective studies with detailed information on nut consumption is warranted given the lack of
data on this association.
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INTRODUCTION
Prostate cancer is the second most common cancer among men worldwide and the
leading cancer among US men. In 2018, the US had over 170,000 new prostate cases, accounting
for almost 1 in 5 new male cancer diagnoses [1]. A recent review of dietary risk factors in
relation to prostate cancer did not find evidence to place nut consumption as a clear risk factor or
as a protective factor [2]. However, nuts have been hypothesized to be associated with a
decreased risk of cancer through multiple mechanisms [2, 3].
Nuts are nutrient dense foods that are rich in important macronutrients and bioactive
compounds, such as unsaturated fatty acids (MUFAs and PUFAs), high-quality vegetable
protein, fiber, minerals, tocopherols, phytosterols, and phenolic compounds [4, 5]. The nutrients
in nuts may modify specific processes related to cancer development, such as the regulation of
cell differentiation and proliferation, reduction of tumor initiation or promotion, DNA protection,
and regulation of immunologic inflammatory responses [4]. Specifically, flavonoids metabolize
and facilitate the elimination of potentially cancerous chemical compounds or their metabolites,
while antioxidant micronutrients may protect against oxidative damage [4, 6]. In vitro data also
suggests that antioxidant micronutrients protect biomolecules that can influence the risk for
cancer development [4, 6]. Additional nutrients found in nuts have other cancer preventative
effects, such as polyphenols which inhibit chemically induced carcinogenesis, folic acid which
reduces DNA damage, and resveratrol which regulates inflammatory response and
immunological activity [7]. Numerous experimental studies in animals and cultures of cell lines
have also indicated that vitamin E, a micronutrient found in high amounts in nuts, can regulate
differentiation and proliferation [6].
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Epidemiologic studies have found inverse associations between nut consumption and risk
of gastric, esophageal, and lung cancers [8, 9]. Nut consumption has also been associated with a
reduced risk of cancer incidence, cancer death, and all-cause mortality [7, 10]. For prostate
cancer, a cross-national study found that prostate cancer mortality was inversely associated with
the consumption of nuts and oilseeds [3]. Two previous case-control studies indicated that
increasing nut consumption was inversely associated with prostate cancer; yet, the studies did not
include consumption on nut butters [11, 12]. However, two prospective cohort studies in the
Health Professionals Follow-up Study found no such association [13, 14]. Based on the limited
research on this topic, in this study we examined nut and nut butter consumption in relation to
prostate cancer risk in the prospective National Institutes of Health (NIH)-AARP Diet and
Health Study cohort.

MATERIALS AND METHODS
Study Population
The NIH-AARP Diet and Health Study is a prospective cohort study established in 1995
to 1996 [15]. The cohort enrolled US adults between the ages of 50 and 71 years residing in six
states (California, Florida, Louisiana, New Jersey, North Carolina, and Pennsylvania) and two
metropolitan areas (Atlanta, GA, and Detroit, MI). The self-administered baseline questionnaire
(BQ) and risk factor questionnaire (RFQ) assessed demographics, lifestyle, and medical
characteristics. The NIH-AARP Diet and Health Study was approved by the Special Studies
Institutional Review Board of the US National Cancer Institute, and all participants provided
written informed consent.

7

A total of 566,407 participants satisfactorily completed the BQ after excluding additional
withdrawals (n=1), duplicate records (n=179), subjects who moved out of study area before
returning BQ (n=321) or were found to have died before study entry (n=261). The RFQ was
mailed to BQ participants without baseline self-reported colon, breast, or prostate cancers for
additional epidemiologic info in 1996 to 1997. A total of 334,905 participants completed the
RFQ after accounting for participants who withdrew from the study (n=3), died (n=1,619), or
moved out of the study area (n=547) before the RFQ. For this analysis, women (n=161,432)
were omitted leaving a population of 175,644 men who satisfactorily completed both the BQ and
RFQ. Further removal of those with follow-up time of less than 0.05 years (n=2,401) left
173,243 men. Finally, after excluding those who did not provide information on nut (n=2,064)
and nut butter (n=1,720) intake, the final analytic populations included 171,179 and 171,523 men
for the two dietary exposures, respectively.

Assessment of Dietary Factors
At baseline, participants completed a validated 124-item food-frequency questionnaire
regarding dietary intake over the previous 12 months. [16]. Participants were asked how often
they consumed nuts or nut butter, with regard to both portion size and frequency. Nut
consumption was defined as “peanuts, walnuts, seeds, or other nuts” measured in one-fourth cup
increments and peanut butter consumption was defined as “peanut butter or other nut butter”
measured in tablespoon increments. The frequency categories ranged from never to ≥2 times per
day, while portion sizes were less than ¼ cup to more than ½ cup for nuts and less than 1
tablespoon to more than 2 tablespoons for nut butter. We used the following USDA conversions
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from grams for nuts and nut butter: quarter cup of nuts equal to 32.7 grams and one tablespoon
of nut butter equal to 16 grams.

Ascertainment of Prostate Cancer and Cohort Follow-up
Cancer registry linkages from eight states (California, Florida, Louisiana, New Jersey,
North Carolina, Pennsylvania, Georgia, and Michigan) were conducted to obtain cancer
diagnosis information. The analyses in the study were completed for the following categories of
incident prostate cancer: overall, adenocarcinoma, localized, advanced, fatal, low-grade (Gleason
2-7), and high-grade (Gleason ³8). Overall incident prostate cancer (n=18,619) was defined by
registry confirmation, Surveillance, Epidemiology and End Results (SEER) mid-level detail
cancer site group of first registry reported cancer, and SEER cancer site code in accordance with
the International Classification of Diseases for Oncology (ICD-O-3). The cancer endpoint is
defined as carcinoma in situ via the cancer registry, 26 in the SEER cancer site group of first
registry, C619 in the ICD-O-3 cancer site group, and 28010 in the SEER cancer site recode in
ICD-O-3. Localized prostate cancer was defined as stage T1 or T2, N0, M0 and Gleason score of
2-7 at diagnosis (n=1,590) while advanced prostate cancer was defined as stage T3 or T4, N1,
M1, or Gleason score of 8 or more at diagnosis (n=2,502). Fatal cancer was defined as those with
a cause of death listed as prostate cancer death in the NDI (n=738).
Participants from the NIH-AARP Diet and Health Study were followed from the return of
the RFQ until diagnosis, death, relocation outside the registry ascertainment area, or December
31, 2011. Changes in address through linkage were assessed with the US Postal Service, while
vital status were assessed through the National Death Index (NDI) and Social Security
Administration (SSA).
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Statistical Analysis
Cox proportional hazards regression models were used to estimate the hazard ratios
(HRs) and 95% confidence intervals (95% CI) between nut and nut butter consumption and
prostate cancer incidence. Person-years was used as the underlying time metric and was
computed from the date of receiving a valid RFQ until the date of cancer diagnosis, death,
relocation outside ascertainment area, or follow-up end (December 31, 2011), whichever
occurred first. Using the Cox regression model and Kaplan-Meier curves, we evaluated the
proportional hazards assumption.
Dietary variables were energy-adjusted using the multivariate nutrient dense method.
Categorical cut-points for nut, peanut butter, and total nut (nut plus peanut butter) consumption
were based on intake in the analytic cohort, with the first category serving as the referent. The
first category contained non-consumers while the other three categories are based on tertiles of
consumption of nut or peanut butter consumption among consumers of each of these foods. The
median of each category was used to evaluate linear trend. We also assessed the association
using continuous intake measures (1/4 cup for nut consumption and 1 tablespoon for nut butter
consumption). Finally, we examined the association between frequency of nut and peanut butter
consumption in relation to prostate cancer. Categorical cut-points were based on the FFQ
categories (never to 1-6 times per year, 7-11 times per year to 1 time per month, 2-3 times per
month to 1-2 times per week, and 3-4 times per week to 2+ times per day).
We calculated HRs and 95% CI for age-adjusted and multivariate-adjusted models. Our
multivariate models included age, vegetable intake, fruit intake, body mass index (BMI),
calories, alcohol consumption, education level, smoking status, physical activity, race, selfreported health status, cardiovascular disease, diabetes, marriage status, prostate cancer screening
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history, and family prostate cancer history. We also evaluated the Healthy Eating Index 2010
(HEI 2010), monounsaturated (MUFA) and polyunsaturated (PUFA) fatty acids intake,
multivitamin use, fiber, dairy, history of stroke, red meat consumption, height, calcium, betacarotene, alpha-tocopherol, selenium, supplement vitamin D, vitamin D, supplement vitamin E,
and vitamin E as potential confounders, but as these variables did not alter risk estimates by 10%
or more, they were not included in the final multivariate model.
To assess the potential for reverse causality, we conducted a sensitivity analysis in which
we removed the first two years of follow-up. We also evaluated interactions between nut
consumption and age, BMI, race, education, and prostate cancer screening status with likelihood
ratio tests. The statistical significance cutoff for the interaction likelihood ratio test was a P-value
of <0.05.
All statistical analyses were performed using SAS software (Version 9.4). All P-values
were 2-sided, and a P-value of <0.05 was considered statistically significant.

RESULTS
Our population had a median follow-up time of 15.0 (IQR=8.1-15.1) years. The median
age of 173,243 males in our analytic sample was 63.7 (IQR=58.9-67.4) years, with 93.6%
identifying as non-Hispanic white. The mean nut and peanut butter intake among consumers
were 3.4 ± 9.3 and 3.7 ± 8.7 grams per day, respectively. The correlation between nut and peanut
butter consumption was 0.09 (p-value <0.0001).
As shown in Table 1, in general those with higher nut consumption were more likely to
drink more alcohol, have a higher level of education, be more active, eat more meat, consume
more calories, and have higher MUFA and PUFA intake compared to those with low nut
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consumption. They were also less likely to smoke or to have a history of cardiovascular disease,
diabetes, heart disease, and hypertension. Those who consumed more peanut butter were more
likely to drink less alcohol, eat more meat, and have higher MUFA and PUFA intake.
The associations between nut consumption and risk of prostate cancer are shown in Table
2. In our fully adjusted models, there was no association between nut consumption and overall
prostate cancer (highest versus lowest category HR=1.00, 95% CI: 0.95, 1.07). Similarly, no
statistically significant associations between nut consumption and risk of localized, advanced, or
fatal prostate cancer were observed.
The associations between peanut butter consumption and risk of prostate cancer are
shown in Table 3. We did not observe any statistically significant associations between peanut
butter consumption and risk of overall prostate cancer (highest versus lowest category HR=1.02,
95% CI: 0.98, 1.07) or for risk of the subtypes of prostate cancer we evaluated.
Total nut intake (nut and peanut butter) and risk of prostate cancer is summarized in
Table 4. We did not observe an association between total nut intake, and overall prostate cancer
(highest versus lowest category HR=1.00, 95% CI: 0.94, 1.09). There was an inverse association
between total nut intake for the top category of nut consumption compared to no nut intake and
localized prostate cancer (HR: 0.77, 95% CI: 0.60, 0.99). However, the p-trend was not
statistically significant (p-trend=0.36). There was also no association between total nut intake
and risk of advanced or fatal prostate cancer.
Nut consumption frequency was inversely associated with risk of overall prostate cancer
for the higher versus the lowest category (HR: 0.93, 95% CI: 0.88, 0.98), with a borderline
statistically significant p-trend (0.07) (Table 5). There was no association between nut frequency
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and any of the prostate cancer subtypes. We also assessed absolute nut intake in which nut intake
was not energy adjusted and found no statistically significant associations (data now shown).
To account for reverse causality, the association between nut and peanut butter intake,
and risk of prostate cancer was examined after exclusion of the first two years of follow-up
(Supplemental Table 1). This sensitivity analysis did not alter the results.
There were no statistically significant interactions with age, BMI, race, screening status,
education attainment, and family history of prostate cancer, and nut intake (data not shown).

DISCUSSION
In this large prospective cohort study, we did not observe an association between nut and
peanut butter intake and risk of overall prostate cancer. There was limited evidence of an inverse
association with the highest category of total nuts and localized prostate cancer as well as the
highest level of nut consumption frequency and overall prostate cancer, but the linear trends
were not statically significant for both of these measures of nut consumption. To our knowledge,
this study is the largest prospective study to examine the association for nuts and peanut butter in
relation to overall prostate cancer and by prostate cancer subtypes.
Previous studies have found an inverse association between nut consumption and other
cancers including gastric, esophageal, and lung [8, 9]. However, inconsistent results have been
observed for prostate cancer. An analysis that combined three case-control studies in Canada
found that increasing intake of combined beans, lentils, and nuts was inversely associated with
risk of prostate cancer (OR: 0.69; 95% CI: 0.53-0.91) [11]. Given that nuts were combined with
other foods in this study, the results are difficult to compare to other studies. In another casecontrol study in Canada, nut intake greater than 3.0 grams a day associated with decreased
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prostate cancer risk (OR: 0.43; 95% CI: 0.22-0.85) [12]. It is important to consider that these
case-control studies are potentially subject to recall bias. Our largely null results align with two
prior prospective studies among Adventist men in California [14] and men in the Health
Professionals Follow-up Study [13]. The study of Adventist men was limited by a small number
of cases (n=180) and both of these existing cohort studies evaluated intake as frequency of nut
consumption only and did not include nut butters.
We did observe some limited evidence of an inverse association with the highest level of
total nuts and localized prostate cancer, and most frequent nut consumption category and overall
prostate cancer. However, for each of these associations, there was no statically significant linear
trend. While we did not evaluate this in the present study, there are some data to support an
inverse association between nut consumption after prostate cancer diagnosis and all-cause
mortality from the Health Professionals Follow-Up Study [17]. Nut consumption has also been
associated with a reduced risk of overall cancer incidence and cancer death, and all-cause
mortality [7, 10].
There are multiple hypotheses surrounding potential anticancer properties of nuts.
Growing evidence of the role of inflammation and oxidative stress in the development of specific
cancer types point toward antioxidative and anti-inflammatory properties of nuts as a mechanism
[18]. In vitro data has shown that antioxidant micronutrients may protect against oxidative
damage thereby impacting cancer development [6]. Other nut phytochemicals have also been
shown to have anticancer properties. Resveratrol induces apoptosis, inhibits cell invasion, and
angiogenesis in in vivo models for breast, colorectal, liver, pancreatic, and prostate cancer
through the inhibition of molecular targets [18, 19]. Phytoestrogens also act as estrogen
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antagonists that may have protective action in hormone-dependent diseases, including prostate,
breast, and bowel cancer [18].
The strengths of this study include the large sample size, prospective design, and long
follow-up time that increased our power to detect even modest associations. We also had
extensive data on dietary and lifestyle factors to assess for potential confounders. Our data on nut
consumption included both frequency and portion size, and included questions on nuts as well as
peanut butter. Furthermore, we had detailed disease data to be able to evaluate total prostate as
well as prostate cancer subtypes. Further strengths include no recall bias, which may explain
some of the differences between the cohort and case-control findings pertaining to this
association, and the ability to assess reverse causality.
Our study also had some limitations. We only had dietary data from one timepoint, so we
could not assess the impact of changes in nut consumption over time. While our models
accounted for numerous potential confounders, residual confounding might still be present. The
generalizability of the cohort is also limited as the majority of the NIH-AARP study is nonHispanic white. Furthermore, while the FFQ was expansive, it did not ask participants to report
on different types of nuts separately. In addition, FFQs are subject to nondifferential
misclassification which may have biased our results toward the null.
In conclusion, nut and peanut butter consumption were not clearly associated with
prostate cancer risk in this large prospective cohort. Additional prospective studies with detailed
nut consumption data are still warranted to clarify this association, as few studies have addressed
this question.
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TABLE 1 Baseline characteristics of participants by categories of dietary nut and peanut butter intake in the NIH-AARP Diet and Health Study1
Nut Intake (n=171,179)
Peanut Butter Intake (n=171,523)
Nut or peanut butter intake,
g/1000 kcal
Age at baseline, y
BMI, kg/m2
Race
Non-Hispanic White
Non-Hispanic Black
Other
Smoking
Never
Former
≤20 cigarettes/d
>20 cigarettes/d
Current
≤20 cigarettes/d
>20 cigarettes/d
Education, %
Less than high school
Completed high school
Post-high school or some college
College and postgraduate
Physical activity, %
Never/Rarely
1-3 times/mo
1-2 times/wk
3-4 times/wk
≥5 times/wk
Calories, kcal/d
Vegetable intake, servings/d
Fruit intake, servings/d
Red meat intake, g/d
Alcohol, g/d
MUFA intake, g/d
PUFA intake, g/d
HEI 2010
Self-reported history, %
Heart disease
Diabetes
Stroke
Hypertension
Screening, %
Prostate cancer family history, %

C1 (n=14,570)

C2 (n=51,854)

C3 (n=51,537)

C4 (n=53,218)

C1 (n=38,528)

C2 (n=44,279)

C3 (n=43,545)

C4 (n=45,171)

0

0.12 (0.06, 0.19)

0.57 (0.43, 0.77)

2.55 (1.57, 4.64)

0

0.15 (0.09, 0.25)

0.78 (0.54, 1.09)

3.71 (2.41, 6.99)

63.9 (59.0, 67.3)
26.3 (24.1, 29.2)

63.3 (58.5, 67.0)
26.5 (24.3, 29.1)

62.7 (57.9, 66.6)
26.6 (24.5, 29.4)

63.1 (58.3, 66.8)
26.6 (24.4, 29.2)

63.4 (58.5, 67.0)
26.2 (24.2, 28.7)

62.7 (57.8, 66.7)
26.6 (24.4, 29.3)

63.1 (58.2, 66.8)
26.6 (24.4, 29.4)

63.4 (58.6, 66.9)
26.6 (24.4, 29.3)

93.3
2.2
3.3

93.7
2.2
3.3

94.3
2.0
2.9

93.6
2.4
3.2

91.8
2.2
4.9

92.7
2.7
3.6

94.4
2.2
2.5

95.7
1.7
1.8

26.5

29.9

30.3

30.5

30.6

30.0

29.6

29.6

26.6
31.0

29.2
28.2

29.3
28.0

29.6
28.1

28.4
29.7

29.6
28.2

29.8
27.6

28.7
27.9

6.6
5.3

5.5
3.9

5.2
3.8

4.9
3.8

4.5
3.2

5.1
3.7

5.5
4.2

5.9
4.6

8.6
29.4
22.2
37.0

5.3
25.5
22.3
44.6

4.3
23.0
22.1
48.7

3.4
20.8
21.5
52.5

4.7
22.0
21.0
50.2

4.6
23.1
21.7
48.5

4.6
24.2
22.7
46.4

4.8
24.9
22.4
45.8

20.4
11.3
17.0
25.9
24.8
1730 (1305, 2279)
3.2 (2.1, 4.9)
2.4 (1.3, 4.0)
49.2 (22.2, 89.2)
1.5 (0, 12.2)
18.9 (12.6, 28.2)
11.2 (7.8, 16.2)
65.1 (55.7, 72.6)

14.4
13.0
21.4
28.6
22.0
1799 (1391, 2296)
3.4 (2.3, 4.8)
2.4 (1.4, 3.8)
58.2 (32.5, 94.9)
3.2 (0.51, 16.5)
21.2 (15.0, 29.6)
12.4 (8.9, 17.1)
65.5 (57.0, 72.6)

13.0
13.2
22.8
29.3
21.3
1885 (1448, 2447)
3.6 (2.4, 5.1)
2.4 (1.5, 3.8)
66.3 (38.7, 106.2)
4.3 (0.69, 17.2)
23.6 (16.6, 32.9)
13.8 (9.8, 19.0)
65.9 (58.0, 72.6)

11.8
12.3
22.5
30.0
22.9
1951 (1547, 2484)
3.7 (2.6, 5.3)
2.5 (1.5, 3.9)
67.0 (38.5, 106.4)
5.2 (0.78, 18.7)
26.0 (18.9, 35.6)
15.5 (11.3, 21.1)
68.2 (60.8, 74.7)

14.7
11.4
19.6
28.2
25.3
1746 (1346, 2247)
3.5 (2.3, 5.1)
2.6 (1.5, 4.1)
51.6 (24.8, 91.1)
4.7 (0.56, 19.2)
19.1 (13.0, 27.5)
11.5 (8.1, 16.2)
66.5 (58.0, 73.5)

13.3
13.2
22.4
28.9
21.7
1959 (1486, 2456)
3.6 (2.5, 5.2)
2.5 (1.5, 4.0)
64.4 (36.5, 104.2)
4.9 (0.77, 19.7)
23.2 (16.1, 32.1)
13.6 (9.6, 18.6)
65.5 (57.1, 72.4)

13.5
13.4
22.7
29.3
20.5
1734 (1409, 2277)
3.4 (2.3, 4.8)
2.4 (1.4, 3.7)
63.7 (38.6, 100.9)
3.6 (0.56, 16.0)
22.5 (16.5, 31.1)
13.2 (9.7, 18.2)
66.1 (58.2, 72.7)

13.2
12.6
22.1
29.4
22.1
2015 (1563, 2517)
3.6 (2.4, 5.0)
2.4 (1.4, 3.7)
68.1 (40.0, 106.5)
2.9 (0.28, 14.2)
27.6 (20.1, 37.1)
16.1 (11.8, 21.5)
67.9 (60.3, 74.4)

26.3
13.5
3.4
45.2
84.3
7.1

19.1
9.0
2.2
41.2
87.0
8.3

16.3
9.0
1.8
40.1
87.8
8.5

15.0
9.8
1.7
38.5
88.1
8.7

20.7
9.8
2.3
41.9
87.4
7.8

16.5
8.2
1.9
40.8
87.4
8.4

17.2
9.4
1.9
40.3
87.6
8.6

16.5
11.1
2.1
38.8
87.0
8.7

NOTE: Some percentages do not sum to 100 due to missing data and rounding.
1
Values are presented as either median (IQR) or percentages. Intake density is based on gram per 1000 kcal. C, category. HEI 2010, Healthy Eating Index 2010.
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TABLE 2 Hazard ratios and 95% confidence intervals for risk of prostate cancer associated with nut intake (N=171,179)1
Nut Intake

Median nut intake, g/1000 kcal
Person-years, n
Overall
Cases (n)
Age-Adjusted HR (95% CI)3
Multivariable-Adjusted HR (95% CI)4
Localized
Cases (n)
Age-Adjusted HR (95% CI)3
Multivariable-Adjusted HR (95% CI)4
Advanced
Cases (n)
Age-Adjusted HR (95% CI)3
Multivariable-Adjusted HR (95% CI)4
Fatal
Cases (n)
Age-Adjusted HR (95% CI)3
Multivariable-Adjusted HR (95% CI)4

P for trend2

Continuous (every quarter
cup, or 32.75 g/1000 kcal)

5,707
1.08 (1.02, 1.14)
1.00 (0.95, 1.07)

0.41
0.04

0.99 (0.99, 1.00)
0.99 (0.98, 1.00)

488
0.98 (0.81, 1.19)
0.88 (0.72, 1.07)

482
0.93 (0.77, 1.13)
0.83 (0.68, 1.01)

0.44
0.18

0.98 (0.96, 1.01)
0.99 (0.96, 1.01)

618
1.15 (0.96, 1.38)
1.11 (0.92, 1.33)

629
1.18 (0.99, 1.42)
1.13 (0.94, 1.36)

637
1.14 (0.95, 1.37)
1.09 (0.90, 1.30)

0.86
0.84

1.00 (0.98, 1.02)
1.00 (0.98, 1.02)

211
0.81 (0.62, 1.06)
0.84 (0.64, 1.11)

211
0.84 (0.65, 1.10)
0.89 (0.68, 1.17)

235
0.88 (0.68, 1.15)
0.93 (0.71, 1.22)

0.68
0.50

1.01 (0.97, 1.04)
1.01 (0.97, 1.04)

C1

C2

C3

C4

0
162,143

0.12
601,356

0.57
602,350

2.55
624,987

1,390
1
1

5,667
1.11 (1.05, 1.18)
1.05 (0.99, 1.11)

5,654
1.12 (1.06, 1.19)
1.05 (0.99, 1.11)

129
1
1

476
0.96 (0.79, 1.17)
0.87 (0.72, 1.06)

146
1
1
73
1
1

1

Intake density is based on gram per 1000 kcal. C, category.
Median was used to assess linear trend.
3
Age-adjusted model adjusted for age (years).
4
Multivariable model adjusted for age (continuous, years), BMI (continuous, kg/m2), calories (continuous, kcal/day), education (less than high school,
completed high school, post high school or some college, college and postgraduate), smoking status (never, former ≤20 cigarettes/day, former >20
cigarettes/day, current ≤20 cigarettes/day, current >20 cigarettes/day) , physical activity (never/rarely, 1-3 times/month, 1-2 times/week, 3-4 times/week,
≥5 times/week), race (non-Hispanic white, non-Hispanic black, other), self-reported health (excellent/very good, good, poor/fair), cardiovascular disease,
marital status, prostate cancer screening, family history of prostate cancer and vegetable, fruit, and alcohol intake (continuous).
2
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TABLE 3 Hazard ratios and 95% confidence intervals for risk of prostate cancer associated with peanut butter intake (N=171,523)1
Peanut Butter Intake

Median nut intake, g/1000 kcal
Person-years, n
Overall
Cases (n)
Age-Adjusted HR (95% CI)3
Multivariable-Adjusted HR (95% CI)4
Localized
Cases (n)
Age-Adjusted HR (95% CI)3
Multivariable-Adjusted HR
(95% CI)4
Advanced
Cases (n)
Age-Adjusted HR (95% CI)3
Multivariable-Adjusted HR (95% CI)4
Fatal
Cases (n)
Age-Adjusted HR (95% CI)3
Multivariable-Adjusted HR (95% CI)4

P for trend2

Continuous (every 1
tablespoon, or 16 g/1000 kcal)

4,850
1.03 (0.98, 1.07)
1.02 (0.98, 1.07)

0.93
0.77

0.96 (0.90, 1.02)
0.97 (0.91, 1.03)

407
1.01 (0.88, 1.17)
0.99 (0.86, 1.15)

401
0.97 (0.84, 1.12)
0.96 (0.83, 1.11)

0.60
0.62

0.99 (0.80, 1.23)
1.01 (0.82, 1.26)

551
1.12 (0.99, 1.27)
1.10 (0.97, 1.25)

500
1.04 (0.91, 1.18)
1.02 (0.89, 1.16)

555
1.11 (0.97, 1.25)
1.09 (0.96, 1.24)

0.37
0.41

1.01 (0.84, 1.21)
1.02 (0.84, 1.23)

187
1.07 (0.86, 1.32)
1.04 (0.84, 1.29)

182
1.04 (0.84, 1.29)
1.00 (0.81, 1.24)

205
1.11 (0.90, 1.37)
1.08 (0.88, 1.34)

0.39
0.46

1.05 (0.77, 1.41)
1.05 (0.77, 1.42)

C1

C2

C3

C4

0
448,342

0.15
520,013

0.78
505,046

3.71
520,897

4,055
1
1

4,842
1.04 (1.00, 1.09)
1.03 (0.98, 1.07)

4,703
1.04 (0.99, 1.08)
1.02 (0.98, 1.07)

357
1
1

415
0.99 (0.86, 1.14)
0.98 (0.85, 1.13)

431
1
1
158
1
1

1

Intake density is based on gram per 1000 kcal. C, category.
Median was used to assess linear trend.
3
Age-adjusted model adjusted for age (years).
4
Multivariable model adjusted for age (continuous, years), BMI (continuous, kg/m2), calories (continuous, kcal/day), education (less than high school,
completed high school, post high school or some college, college and postgraduate), smoking status (never, former ≤20 cigarettes/day, former >20
cigarettes/day, current ≤20 cigarettes/day, current >20 cigarettes/day) , physical activity (never/rarely, 1-3 times/month, 1-2 times/week, 3-4 times/week, ≥5
times/week), race (non-Hispanic white, non-Hispanic black, other), self-reported health (excellent/very good, good, poor/fair), cardiovascular disease, marital
status, prostate cancer screening, family history of prostate cancer and vegetable, fruit, and alcohol intake (continuous).
2
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Table 4 Hazard ratios and 95% confidence intervals for risk of prostate cancer according to total nut intake1
Total Nut Intake
Person-years, n
Overall
Cases (n)
Age-Adjusted HR (95% CI)3
Multivariable-Adjusted HR (95% CI)4
Localized
Cases (n)
Age-Adjusted HR (95% CI)3
Multivariable-Adjusted HR (95% CI)4
Advanced
Cases (n)
Age-Adjusted HR (95% CI)3
Multivariable-Adjusted HR (95% CI)4
Fatal
Cases (n)
Age-Adjusted HR (95% CI)3
Multivariable-Adjusted HR (95% CI)4

P for trend2

C1
80,841

C2
632,269

C3
632,815

C4
633,335

700
1
1

5,920
1.09 (1.01, 1.18)
1.03 (0.96, 1.12)

5,861
1.09 (1.00, 1.17)
1.02 (0.95, 1.11)

5,840
1.07 (0.99, 1.15)
1.00 (0.93, 1.09)

0.20
0.09

71
1
1

506
0.89 (0.70, 1.15)
0.82 (0.64, 1.05)

508
0.89 (0.70, 1.14)
0.80 (0.62, 1.03)

486
0.86 (0.67, 1.10)
0.77 (0.60, 0.99)

0.47
0.36

63
1
1

656
1.34 (1.04, 1.74)
1.26 (0.97, 1.63)

631
1.30 (1.00, 1.68)
1.21 (0.93, 1.57)

673
1.36 (1.05, 1.76)
1.27 (0.98, 1.65)

0.59
0.64

29
1
1

222
1.02 (0.69, 1.49)
0.99 (0.67, 1.46)

239
1.11 (0.75, 1.63)
1.08 (0.73, 1.59)

236
1.06 (0.72, 1.56)
1.04 (0.70, 1.54)

0.88
0.80

1

Intake density is based on gram per 1000 kcal. Q, quartile.
Median was used to assess linear trend.
3
Age-adjusted model adjusted for age (years).
4
Multivariable model adjusted for age (years), BMI (kg/m2), calories (kcal/day), education, smoking status, physical activity, race,
self-reported health, cardiovascular disease, marriage, prostate cancer screening, family history of prostate cancer and vegetable, fruit,
and alcohol intake.
2
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Table 5 Hazard ratios and 95% confidence intervals for risk of prostate cancer associated with nut consumption frequency

Frequency
Person-years, n
Overall Prostate Cancer
Cases (n)
Age-Adjusted HR (95% CI)1
Multivariable-Adjusted HR (95% CI)2
Localized Prostate Cancer
Cases (n)
Age-Adjusted HR (95% CI) 1
Multivariable-Adjusted HR (95% CI)2
Advanced
Cases (n)
Age-Adjusted HR (95% CI) 1
Multivariable-Adjusted HR (95% CI)2
Fatal
Cases (n)
Age-Adjusted HR (95% CI) 1
Multivariable-Adjusted HR (95% CI)2

C1
Never to 1-6
times per year
608,146

C2
7-11 times per year
to 1 time per month
597,366

Nut Frequency
C3
2-3 times per month to
1-2 times per week
615,392

C4
3-4 times per week to
2+ times per day
184,167

5,483
1
1

5,616
1.06 (1.02, 1.10)
1.03 (0.99, 1.07)

5,783
1.05 (1.01, 1.09)
1.00 (0.96, 1.04)

1,663
0.98 (0.93, 1.04)
0.93 (0.88, 0.98)

0.50
0.07

484
1
1

470
0.97 (0.86, 1.10)
0.93 (0.82, 1.06)

481
0.97 (0.85, 1.10)
0.92 (0.81, 1.05)

148
1.00 (0.83, 1.20)
0.94 (0.78, 1.14)

0.80
0.28

594
1
1

620
1.08 (0.96, 1.20)
1.05 (0.94, 1.18)

649
1.08 (0.97, 1.21)
1.04 (0.93, 1.17)

181
0.98 (0.83, 1.16)
0.93 (0.78, 1.10)

0.58
0.84

242
1
1

205
0.90 (0.75, 1.09)
0.92 (0.76, 1.11)

211
0.88 (0.73, 1.06)
0.91 (0.75, 1.10)

77
1.00 (0.77, 1.29)
1.03 (0.79, 1.35)

0.46
0.72

P for trend

1

Age-adjusted model adjusted for age (years).
Multivariable model adjusted for age (years), BMI (kg/m2), calories (kcal/day), education, smoking status, physical activity, race, selfreported health, cardiovascular disease, marriage, prostate cancer screening, family history of prostate cancer and vegetable, fruit, and
alcohol intake.
2
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SUPPLEMENTAL TABLE 1 Hazard ratios and 95% confidence intervals for risk of prostate cancer associated with nut and peanut butter consumption after exclusion of first 2
years of follow-up1
Nut Intake
Person-years, n
Overall
Cases (n)
Age-Adjusted HR (95% CI)2
Multivariable-Adjusted HR (95% CI)3
Localized
Cases (n)
Age-Adjusted HR (95% CI)2
Multivariable-Adjusted HR (95% CI)3
Advanced
Cases (n)
Age-Adjusted HR (95% CI)2
Multivariable-Adjusted HR (95% CI)3
Fatal
Cases (n)
Age-Adjusted HR (95% CI)2
Multivariable-Adjusted HR (95% CI)3

Peanut Butter Intake
C3
419,562

C1
133,619

C2
499,636

C3
501,033

C4
520,409

C1
372,693

C2
432,985

C4
432,252

1,222
1
1

5,029
1.11 (1.05, 1.18)
1.04 (0.98, 1.11)

5,060
1.13 (1.06, 1.20)
1.05 (0.99, 1.12)

5,090
1.08 (1.02, 1.15)
1.01 (0.94, 1.07)

3,597
1
1

4,299
1.04 (1.00, 1.09)
1.02 (0.98, 1.07)

4,182
1.04 (0.99, 1.08)
1.02 (0.98, 1.07)

4,354
1.04 (0.99, 1.09)
1.03 (0.99, 1.08)

129
1
1

476
0.96 (0.79, 1.17)
0.87 (0.72, 1.06)

488
0.98 (0.81, 1.19)
0.88 (0.72, 1.07)

482
0.93 (0.77, 1.13)
0.83 (0.68, 1.01)

357
1
1

415
0.99 (0.86, 1.14)
0.98 (0.85, 1.13)

407
1.01 (0.88, 1.17)
0.99 (0.86, 1.15)

401
0.97 (0.84, 1.12)
0.96 (0.83, 1.11)

127
1
1

545
1.16 (0.95, 1.40)
1.11 (0.91, 1.34)

571
1.22 (1.01, 1.48)
1.16 (0.96, 1.41)

567
1.16 (0.96, 1.40)
1.09 (0.90, 1.33)

391
1
1

486
1.09 (0.95, 1.24)
1.07 (0.93, 1.22)

443
1.01 (0.88, 1.16)
1.00 (0.87, 1.15)

498
1.09 (0.96, 1.25)
1.08 (0.95, 1.24)

59
1
1

164
0.77 (0.57, 1.04)
0.80 (0.59, 1.08)

183
0.89 (0.67, 1.20)
0.93 (0.69, 1.26)

194
0.89 (0.67, 1.19)
0.93 (0.69, 1.25)

132
1
1

151
1.03 (0.81, 1.30)
1.00 (0.79, 1.27)

151
1.03 (0.82, 1.30)
1.01 (0.80, 1.28)

169
1.10 (0.87, 1.38)
1.08 (0.85, 1.36)

1

Intake density is based on gram per 1000 kcal. C, category.
Age-adjusted model adjusted for age (years).
3
Multivariable model adjusted for age (continuous, years), BMI (continuous, kg/m2), calories (continuous, kcal/day), education (less than high school, completed high school, post high
school or some college, college and postgraduate), smoking status (never, former ≤20 cigarettes/day, former >20 cigarettes/day, current ≤20 cigarettes/day, current >20 cigarettes/day) ,
physical activity (never/rarely, 1-3 times/month, 1-2 times/week, 3-4 times/week, ≥5 times/week), race (non-Hispanic white, non-Hispanic black, other), self-reported health
(excellent/very good, good, poor/fair), cardiovascular disease, marital status, prostate cancer screening, family history of prostate cancer and vegetable, fruit, and alcohol intake
(continuous).
2
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